Incyte Names First-Ever Ingenuity Awards Winners in Hidradenitis Suppurativa

Incyte has announced the winners of its first-ever Ingenuity Awards in hidradenitis suppurativa (HS), a new company-sponsored program The Dermatology Digest reported on this week.

The awards mark the launch of a fresh funding-and-recognition vehicle from the Wilmington, Delaware-based biopharmaceutical company, which has built its dermatology franchise around JAK inhibition. Incyte has not previously run an awards program dedicated to HS, a chronic inflammatory skin disease that affects an estimated 1% of the population and remains one of the most under-treated conditions in the specialty.

Who are the winners?

The Dermatology Digest's report introduces the inaugural class of awardees — the first group to receive the Incyte Ingenuity Awards in HS. The program's name signals its focus: projects that bring new thinking to a disease where treatment options have historically lagged far behind those in psoriasis or atopic dermatitis.

HS care has advanced in recent years, with adalimumab approved for moderate-to-severe disease and bimekizumab gaining traction, but surgical management, pain control and psychosocial support still vary widely across practices. Awards programs like Incyte's aim to surface and fund work that closes those gaps.

Why does a drugmaker fund HS innovation?

Incyte's dermatology portfolio gives it a direct commercial stake in the HS field. Company-sponsored awards serve two functions at once: they accelerate clinical or care-delivery projects, and they deepen the manufacturer's relationships with investigators and clinicians in the therapeutic area.

Readers should note the distinction that matters here — the awards are a manufacturer initiative, not an independent grant program. Incyte selected the winners and set the program's criteria; the projects recognized have not, on the strength of this announcement, passed independent peer review.

What comes next?

The Dermatology Digest's piece serves primarily as an introduction to the inaugural winners and their work. Whether the Ingenuity Awards become an annual fixture, and what funding amounts attach to them, will determine whether the program materially shifts HS research capacity or remains a recognition exercise.

For clinicians managing HS, the immediate takeaway is a new pool of named projects worth watching as the field works toward earlier diagnosis and standardized care pathways.